US PRE-MARKET MOVERS: AZN, CIBR, U, AGX, TRIP
Importance
Level 1
ES -0.4% NQ -0.6% RTY -0.6%
- AZN +3.6%: Tozorakimab met primary endpoint in both OBERON and TITANIA Phase III trials
- CIBR -2.4%: Reports emerge of leaked Anthropic AI model, "Claude Mythos"; co. believes it poses unprecedented cybersecurity risks
- U +14.1%: Raised Q1 revenue view; PT raised at BofA
- AGX +9.5%: Earnings beat; upgraded at JPM to 'Overweight' from 'Neutral'
- TRIP +3.8%: Upgraded at BofA to 'Buy' from 'Neutral'
#AZN#UNITED KINGDOM#EUROPE#JPMORGAN CHASE & CO#ASTRAZENECA PLC#3I GROUP PLC#EQUITIES#EU SESSION#US SESSION#HIGHLIGHTED#RESEARCH SHEET#PHARMACEUTICALS#DIVERSIFIED BANKS#ASSET MANAGEMENT & CUSTODY BANKS#ELECTRIC UTILITIES#PHARMACEUTICALS (GROUP)#BANKS#CAPITAL MARKETS#ELECTRIC UTILITIES (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#BANKS (GROUP)#FINANCIAL SERVICES#UTILITIES (GROUP)#S&P 500 INDEX#NASDAQ 100 INDEX#FTSE 100 INDEX#EVERSOURCE ENERGY#ES#JPM#III#ARTIFICIAL INTELLIGENCE#US PRE-MARKET#US RESEARCH#US EQUITIES